The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.
Elective neck irradiation
Esthesineuroblastoma
Propensity score matching
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
21 Oct 2024
21 Oct 2024
Historique:
received:
27
05
2024
accepted:
13
10
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
21
10
2024
Statut:
epublish
Résumé
This study aims to assess the clinical efficacy of elective neck irradiation (ENI) in patients with esthesineuroblastoma (ENB), a rare malignant neoplasm, who are clinically node-negative. We conducted a retrospective analysis of 178 patients newly diagnosed with ENB at our institution between 2009 and 2021. Propensity score matching (PSM) was employed to compare node-negative patients treated with and without ENI. We extensively examined survival outcomes and treatment failure. Of the 178 participants, 149 (83.7%) were lymph node-negative and staged in Modified Kadish A-C. 96 patients underwent ENI treatment, while 53 did not. At baseline, patients who received ENI differed from those who did not in terms of radiotherapy technique, staging, orbital invasion, surgical mode, and chemotherapy. After PSM, 43 pairs were available for analysis. ENI was observed to extend overall survival (OS, 5-year 73.9% vs. 84.0%; 3-year 76.9% vs. 97.1%, p = 0.022), progression-free survival (PFS, 5-year 38.5% vs. 84.6%; 3-year 50.5% vs. 94.5%, p < 0.001) and locoregional relapse-free survival (LRFS, 5-year 42.7% vs. 84.6%, p = 0.023; 3-year 57.3% vs. 94.5%, p < 0.001) in node-negative ENI patients. Failure pattern analyses revealed that ENI, which included level Ib, II, VIIa, significantly reduced the treatment failure rate. Furthermore, ENI did not significantly impact the prognosis of T1-2 patients, indicating potential clinical value of ENI in T3-4 patients. Our findings suggested that ENI decreased regional failure and significantly enhanced LRFS and PFS. ENI may be considered as an integral part of the initial treatment strategy for locally advanced node-negative ENB patients.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to assess the clinical efficacy of elective neck irradiation (ENI) in patients with esthesineuroblastoma (ENB), a rare malignant neoplasm, who are clinically node-negative.
METHODS
METHODS
We conducted a retrospective analysis of 178 patients newly diagnosed with ENB at our institution between 2009 and 2021. Propensity score matching (PSM) was employed to compare node-negative patients treated with and without ENI. We extensively examined survival outcomes and treatment failure.
RESULTS
RESULTS
Of the 178 participants, 149 (83.7%) were lymph node-negative and staged in Modified Kadish A-C. 96 patients underwent ENI treatment, while 53 did not. At baseline, patients who received ENI differed from those who did not in terms of radiotherapy technique, staging, orbital invasion, surgical mode, and chemotherapy. After PSM, 43 pairs were available for analysis. ENI was observed to extend overall survival (OS, 5-year 73.9% vs. 84.0%; 3-year 76.9% vs. 97.1%, p = 0.022), progression-free survival (PFS, 5-year 38.5% vs. 84.6%; 3-year 50.5% vs. 94.5%, p < 0.001) and locoregional relapse-free survival (LRFS, 5-year 42.7% vs. 84.6%, p = 0.023; 3-year 57.3% vs. 94.5%, p < 0.001) in node-negative ENI patients. Failure pattern analyses revealed that ENI, which included level Ib, II, VIIa, significantly reduced the treatment failure rate. Furthermore, ENI did not significantly impact the prognosis of T1-2 patients, indicating potential clinical value of ENI in T3-4 patients.
CONCLUSIONS
CONCLUSIONS
Our findings suggested that ENI decreased regional failure and significantly enhanced LRFS and PFS. ENI may be considered as an integral part of the initial treatment strategy for locally advanced node-negative ENB patients.
Identifiants
pubmed: 39434155
doi: 10.1186/s13014-024-02539-x
pii: 10.1186/s13014-024-02539-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Subventions
Organisme : National Natural Science Foundation of China
ID : 82303420
Informations de copyright
© 2024. The Author(s).
Références
Rao KR, Upadhya IB. A review on Esthesioneuroblastoma. Indian J Otolaryngol Head Neck Surg. 2022;74:1584–90.
doi: 10.1007/s12070-021-02726-2
pubmed: 36452592
Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007;133:276–80.
doi: 10.1001/archotol.133.3.276
pubmed: 17372086
Ferlito A, Rinaldo A, Rhys-Evans PH. Contemporary clinical commentary: esthesioneuroblastoma: an update on management of the neck. Laryngoscope. 2003;113:1935–8.
doi: 10.1097/00005537-200311000-00015
pubmed: 14603051
Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2:683–90.
doi: 10.1016/S1470-2045(01)00558-7
pubmed: 11902539
Naples JG, Spiro J, Tessema B, Kuwada C, Kuo CL, Brown SM. Neck recurrence and mortality in esthesioneuroblastoma: implications for management of the N0 neck. Laryngoscope. 2016;126:1373–9.
doi: 10.1002/lary.25803
pubmed: 26607219
Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132:134–8.
doi: 10.1001/archotol.132.2.134
pubmed: 16490869
Dias FL, Sa GM, Lima RA, Kligerman J, Leoncio MP, Freitas EQ, et al. Patterns of failure and outcome in esthesioneuroblastoma. Arch Otolaryngol Head Neck Surg. 2003;129:1186–92.
doi: 10.1001/archotol.129.11.1186
pubmed: 14623748
Zanation AM, Ferlito A, Rinaldo A, Gore MR, Lund VJ, McKinney KA, et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. Eur Arch Otorhinolaryngol. 2010;267:1667–71.
doi: 10.1007/s00405-010-1360-6
pubmed: 20706843
pmcid: 3005584
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D, et al. NCCN Guidelines
doi: 10.6004/jnccn.2022.0016
pubmed: 35276673
Chao KS, Kaplan C, Simpson JR, Haughey B, Spector GJ, Sessions DG, et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck. 2001;23:749–57.
doi: 10.1002/hed.1107
pubmed: 11505485
Gallia GL, Reh DD, Salmasi V, Blitz AM, Koch W, Ishii M. Endonasal endoscopic resection of esthesioneuroblastoma: the Johns Hopkins Hospital experience and review of the literature. Neurosurg Rev. 2011;34:465–75.
doi: 10.1007/s10143-011-0329-2
pubmed: 21655908
Brisson RJ, Quinn TJ, Deraniyagala RL. The role of chemotherapy in the management of olfactory neuroblastoma: a 40-year surveillance, epidemiology, and end results registry study. Health Sci Rep. 2021;4:e257.
doi: 10.1002/hsr2.257
pubmed: 33969231
pmcid: 8088587
Cranmer LD, Chau B, Rockhill JK, Ferreira M Jr., Liao JJ. Chemotherapy in Esthesioneuroblastoma/Olfactory neuroblastoma: an analysis of the Surveillance Epidemiology and End results (SEER) 1973–2015 database. Am J Clin Oncol. 2020;43:203–9.
doi: 10.1097/COC.0000000000000649
pubmed: 31842117
Kong KA, Thorp BD, Sheth SH. The role of induction therapy for sinonasal cancers. Curr Treat Options Oncol. 2023;24:162–9.
doi: 10.1007/s11864-022-01046-z
pubmed: 36696082
Nakamura N, Zenda S, Tahara M, Okano S, Hayashi R, Hojo H, et al. Proton Beam therapy for olfactory neuroblastoma. Radiother Oncol. 2017;122:368–72.
doi: 10.1016/j.radonc.2016.12.020
pubmed: 28062086
Hu W, Hu J, Gao J, Yang J, Qiu X, Kong L, et al. Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma. Annals Translational Med. 2020;8:926–926.
doi: 10.21037/atm-19-4790
Morimoto K, Demizu Y, Hashimoto N, Mima M, Terashima K, Fujii O, et al. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skull base invasion. Jpn J Clin Oncol. 2014;44:428–34.
doi: 10.1093/jjco/hyu010
pubmed: 24620027
Rimmer J, Lund VJ, Beale T, Wei WI, Howard D. Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. Laryngoscope. 2014;124:1542–9.
doi: 10.1002/lary.24562
pubmed: 24347437
Ow TJ, Hanna EY, Roberts DB, Levine NB, El-Naggar AK, Rosenthal DI, et al. Optimization of long-term outcomes for patients with esthesioneuroblastoma. Head Neck. 2014;36:524–30.
doi: 10.1002/hed.23327
pubmed: 23780581
De Virgilio A, Costantino A, Sebastiani D, Russo E, Franzese C, Mercante G, et al. Elective neck irradiation in the management of esthesioneuroblastoma: a systematic review and meta-analysis. Rhinology. 2021;59:433–40.
pubmed: 34254061
Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, et al. Esthesioneuroblastoma: the Princess Margaret Hospital experience. Head Neck. 2008;30:1607–14.
doi: 10.1002/hed.20920
pubmed: 18798301
Abdelmeguid AS, Bell D, Roberts D, Ferrarotto R, Phan J, Su SY, et al. Long-term outcomes of olfactory neuroblastoma: MD Anderson Cancer Center Experience and Review of the literature. Laryngoscope. 2022;132:290–7.
doi: 10.1002/lary.29732
pubmed: 34272876
Modesto A, Blanchard P, Tao YG, Rives M, Janot F, Serrano E, et al. Multimodal treatment and long-term outcome of patients with esthesioneuroblastoma. Oral Oncol. 2013;49:830–4.
doi: 10.1016/j.oraloncology.2013.04.013
pubmed: 23747132
de Gabory L, Verillaud B, Rumeau C, Herman P, Jankowski R, Michel J, et al. Multicenter assessment of exclusive endoscopic endonasal approach for the treatment of 53 olfactory neuroblastomas. Head Neck. 2018;40:1000–7.
doi: 10.1002/hed.25064
pubmed: 29356209
Hu W, Hu J, Gao J, Yang J, Qiu X, Kong L, et al. Intensity-modulated particle beam radiation therapy in the management of olfactory neuroblastoma. Ann Transl Med. 2020;8:926.
doi: 10.21037/atm-19-4790
pubmed: 32953726
pmcid: 7475427
Veyrat M, Vérillaud B, Fiaux-Camous D, Froelich S, Bresson D, Nicolai P, et al. Olfactory neuroblastoma. Adv Otorhinolaryngol. 2020;84:154–67.
pubmed: 32731231
Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, et al. Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys. 2010;78:992–7.
doi: 10.1016/j.ijrobp.2009.09.019
pubmed: 20231062
Yin ZZ, Luo JW, Gao L, Yi JL, Huang XD, Qu Y, et al. Spread patterns of lymph nodes and the value of elective neck irradiation for esthesioneuroblastoma. Radiother Oncol. 2015;117:328–32.
doi: 10.1016/j.radonc.2015.10.002
pubmed: 26558687
Rinaldo A, Ferlito A, Shaha AR, Wei WI, Lund VJ. Esthesioneuroblastoma and cervical lymph node metastases: clinical and therapeutic implications. Acta Otolaryngol. 2002;122:215–21.
doi: 10.1080/00016480252814261
pubmed: 11936917
Jiang W, Mohamed ASR, Fuller CD, Kim BYS, Tang C, Gunn GB, et al. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Pract Radiat Oncol. 2016;6:241–7.
doi: 10.1016/j.prro.2015.10.023
pubmed: 26979544
Goshtasbi K, Abiri A, Abouzari M, Sahyouni R, Wang BY, Tajudeen BA, et al. Hyams grading as a predictor of metastasis and overall survival in esthesioneuroblastoma: a meta-analysis. Int Forum Allergy Rhinol. 2019;9:1054–62.
doi: 10.1002/alr.22373
pubmed: 31251848
pmcid: 7276257